Bone Therapeutics is a regenerative therapy company specializing in addressing unmet medical needs in the field of bone diseases and orthopaedics. The company is bringing a new and unique treatment paradigm in this field with novel differentiated bone-forming cells administered via a minimally invasive percutaneous approach, offering significant benefits over the current standard of care which involves heavy surgery and long recovery periods.
Today, Bone Therapeutics has 2 first-in-class products, addressing multiple indications, in clinical development:
With two pivotal “phase III” and two “phase II” trials ongoing, Bone Therapeutics can be considered as the most advanced regenerative company in its field. Moreover, ongoing pre-clinical programs, targeting other indications, and derived products should allow the company to further leverage its unique knowledge of the bone physiology and long-standing expertise in bone regeneration.
Bone Therapeutics’ regenerative products are manufactured to the highest GMP standards, comply with all regulations and are protected by a rich IP estate covering 11 patent families.
Founded in 2006, Bone Therapeutics is privately held and headquartered in Gosselies (south of Brussels), Belgium.